Đang chuẩn bị liên kết để tải về tài liệu:
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: An ancillary study derived from a randomized clinical trial

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel. | Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab An ancillary study derived from a randomized clinical trial

TÀI LIỆU LIÊN QUAN

Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index

Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: A retrospective multi-institutional study on 965 patients

Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy

The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: A companion study to the PePiTA trial

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases

Prognostic models for breast cancer: A systematic review

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials

A predictive and prognostic model for hepatocellular carcinoma with microvascular invasion based TCGA database genomics

Parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor type 1 in locally advanced laryngeal cancer as prognostic indicators of relapse and survival